Published Date: 16 Feb 2023
According to a report by the Alzheimer's Association task force, it's time to reframe what "clinically meaningful" means and change expectations about clinical trials.
Read Full NewsPreschool-aged children exposed to screens for extended daily periods face elevated prevalence of sleep disturbances.
Treatment rates for US adults with psychiatric disorders are modestly higher than in previous decades, but only a third receive minimally adequate care, new research shows.
An Australian-designed smartphone app uses personalized cognitive bias modification to help users reduce or avoid alcohol consumption.
In patients with cancer receiving immune checkpoint inhibitor therapy, osteoarthritis is linked to the risk for inflammatory arthritis immune-related adverse events.
Researchers evaluate the impact of allogeneic stem cell transplantation in chronic myelomonocytic leukemia across BLAST and BLAST-Mol clinical risk models.
1.
Chemicals in Sewage Sludge Fertilizer Pose Cancer Risk, EPA Says
2.
Blinatumomab May Improve Survival in High-Risk Adult B-ALL
3.
Is It Really Cancer? More Concerns About Accelerated Approval; Metformin and Cancer
4.
Increased Exercise May Lower the Risk of Prostate Cancer.
5.
'Full House' Star's Cancer; Fluoride Fears Go Mainstream; Florida Doctor Arrested
1.
Erythropoietic Activity Biomarkers in Functional Hematology
2.
Revolutionizing Thyroid Cancer: Advances in Molecular Genetics and Personalized Treatment Approaches
3.
Cancer Prehabilitation and Functional Recovery Pathways: An Evidence-Based Review
4.
Decoding Granular Cell Tumor: What You Need to Know
5.
Unlocking the Secrets of Hemoglobin: How It Works to Keep Us Healthy
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
1.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
3.
Should We Use DARA Up Front As First-Line Therapy in MM?
4.
Navigating the Complexities of Ph Negative ALL - Part IV
5.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation